Pegfilgrastim (Neulasta) is a long-acting G-CSF given as one 6 mg subcutaneous dose per chemotherapy cycle to reduce febrile neutropenia, and it needs a cold chain.

We do not publish prices. A pegfilgrastim injection price or Neulasta cost for an importer depends on whether you want the originator Neulasta, a regulator-approved biosimilar or an Indian-made 6 mg line, the presentation (plain prefilled syringe or the Onpro kit), the quantity, the registration route in your destination, 2 to 8 °C cold-chain freight and Incoterms. M Care Exports quotes per destination once you send the brand or line, the volume and the country.

The non-proprietary name is pegfilgrastim, and Neulasta from Amgen is the originator brand. In the US, DailyMed carries FDA labels for pegfilgrastim biosimilars to Neulasta, including Fulphila, Udenyca, Ziextenzo, Nyvepria, Fylnetra, Stimufend and Armlupeg. The EMA lists biosimilars of Neulasta that are authorised in the EU, including Pelgraz, Ziextenzo, Fulphila, Pelmeg, Grasustek, Cegfila, Nyvepria and Stimufend. These are biosimilars, not generics. M Care Exports confirms which of them, and which Indian-made lines such as Peg-ReliGrast, Imupeg and Pegg Trust, we can supply for your destination.

We compare on label facts only and do not recommend one over the other. The US Neulasta label gives 6 mg subcutaneously once per chemotherapy cycle in a 6 mg/0.6 mL prefilled syringe, with an Onpro kit option. The US Neupogen label (filgrastim, Amgen) gives a starting dose of 5 mcg/kg/day as a single daily subcutaneous injection, short IV infusion or continuous IV infusion, in vials and prefilled syringes of 300 mcg and 480 mcg. Both labels cover febrile neutropenia in non-myeloid cancer patients on myelosuppressive chemotherapy, and Neupogen also lists indications such as AML induction or consolidation chemotherapy, bone marrow transplantation, progenitor cell mobilisation and severe chronic neutropenia. Neulasta is not indicated for progenitor cell mobilisation. Check each label for your destination. See the filgrastim page.

The US label gives 6 mg subcutaneously once per chemotherapy cycle for adults and for paediatric patients weighing at least 45 kg, not between 14 days before and 24 hours after chemotherapy. The UK SmPC gives one 6 mg prefilled syringe per cycle, at least 24 hours after cytotoxic chemotherapy. Neulasta Onpro is the US kit that co-packs the 6 mg/0.6 mL prefilled syringe with an on-body injector. The UK SmPC we fetched does not mention it, so confirm that your destination registers the Onpro kit before ordering.

The US label says to store at 2 to 8 °C in the original carton, protected from light, not frozen and not shaken. It says to discard a syringe or vial left at room temperature for more than 48 hours, and not to hold the Onpro kit at room temperature for more than 12 hours before use. The UK SmPC allows one period of up to 72 hours not above 30 °C. Key US warnings include splenic rupture, acute respiratory distress syndrome, serious hypersensitivity including anaphylaxis and sickle cell crises. This is not a full side-effect list, so the full label governs use.

M Care Exports supplies both originator or regulator-approved brands and Indian-made lines. Examples of Indian-made 6 mg injections are Peg-ReliGrast, Imupeg and Pegg Trust. We supply them for destinations whose registration accepts them and make no claim that they are registered in any particular country. If you need Neulasta, a named biosimilar or an Indian-made line, tell us the destination and quantity, and we confirm what your regulator allows, including any named-patient route, before we quote.